E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

Accuray Announces Results for Second Quarter of Fiscal 2009

ACCURAY (ARAY) - Today
NASDAQ:ARAY $6.89 ($+0.05 +0.7309%)
Open: 6.83 Prev. Close: 6.84
Day's High: 6.99 Low: 6.83
Day's Volume: 398,616
Get a detailed quote onARAY

SUNNYVALE, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Accuray Incorporated ( ARAY), a global leader in the field of radiosurgery, announced today financial results for the second quarter of fiscal 2009, ended December 27, 2008.

For the second quarter of fiscal 2009, Accuray reported total revenue of $57.6 million, a 10.8 percent increase over second quarter of fiscal 2008 total revenue of $52.0 million and a 3.2 percent sequential increase over the first quarter of fiscal 2009.

In the second quarter of fiscal 2009, Accuray recorded a market fair value charge of $860,000, or $0.02 per share, in connection with a settlement agreement entered into with the distributor of the auction rate securities that guarantees repayment of the securities at par value beginning in June 2010. As a result net income for the second quarter of fiscal 2009 was $1.4 million, or $0.02 per diluted share, compared to net income of $2.3 million, or $0.04 per diluted share, during the same period last year. Non-cash, stock based compensation charges for the second quarter of fiscal 2009 were $3.6 million.

For the six months ended December 27, 2008, total revenue was $113.5 million, a 12.7 percent increase over total revenue of $100.7 million for the same period last year. Net loss for the first half of fiscal 2009 was $1.8 million, or a loss of $0.03 per diluted share, compared to net income of $4.6 million, or $0.08 per diluted share, for the first half of fiscal 2008. The net loss in the first six months of fiscal 2009 was primarily driven by non- recurring costs associated with employee separation expenses and inventory write downs incurred during the fiscal first quarter of 2009.

"We are encouraged by the year-over-year revenue growth plus strong installation and shipment numbers for the quarter, reflecting an expanding demand for our CyberKnife(R) Robotic Radiosurgery System," said Euan S. Thomson Ph.D., Accuray's president and chief executive officer.

In an effort to contain costs, Accuray has eliminated approximately 60 positions or approximately 13 percent of its U.S. workforce. The Company is focused on improving processes and cross-company collaboration with the goal of raising efficiency, and has taken these actions to enhance the Company's success in the long term and position itself to weather the potential impact of the current global downturn. The Company estimates that the future savings in employment related expenses will be approximately $8.7 million per year. Due to severance pay and the timing of employment terminations, limited savings will begin in the fourth fiscal quarter of 2009 with the full benefit starting in the first quarter of fiscal 2010. Most of the affected jobs are located at Accuray's Sunnyvale, Calif. headquarters.

At December 27, 2008, non-contingent contracts, for which all contractual obligations have been satisfied, accounted for approximately $452 million or 76 percent of total backlog. Accuray's backlog is composed of signed contracts that the company believes have a substantially high probability of being recognized as revenue in future periods. Total backlog at the end of the second fiscal quarter of 2009 was $598 million, with approximately $311 million associated with CyberKnife Robotic Radiosurgery System contracts and approximately $287 million associated with services and other recurring revenue. Contingent contracts made up $146 million of backlog.

Accuray's cash and investment balances at the end of the second quarter of 2009 totaled $154.7 million, which includes cash and cash equivalents of $29.4 million, restricted cash of $0.6 million, short-term investments of $80.2 million and long-term investments of $44.5 million. At the end of the second quarter of 2009 the Company continued to have zero debt.

Outlook

The following statement is forward-looking and actual results may differ materially. Accuray expects total revenues for fiscal 2009 to be in the range of $230 million to $250 million.

Additional Information

Additional information regarding backlog segmentation, which will be discussed during the conference call, is available in the Investor Relations section of the company's Web site at http://www.accuray.com.

Earnings Call Open to Investors

Accuray will hold a conference call for financial analysts and investors on Thursday January 29, 2009 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are 1-866-379-2019 (USA) or 1-706-634-1525 (International), Conference ID: 80572858. A live webcast of the call will also be available from the Investor Relations section on the company's Web site at http://www.accuray.com. In addition, a recording of the call will be available by calling 1-800-642-1687 (USA) or 1-706-645-9291(International), Conference ID number: 80572858, beginning at 5:00 p.m. PT 8:00 p.m. ET, January 29, 2009 and will be available through February 1, 2009. A webcast replay will also be available from the Investor Relations section of the company's Web site at http://www.accuray.com from approximately 5:00 p.m. PT / 8:00 p.m. ET today through Accuray's release of its results for the third quarter of fiscal 2009, ending March 28, 2009.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated ( ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently 155 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to financial guidance including realization of backlog, anticipated cost savings and benefits from job eliminations, procedure growth, market acceptance; clinical studies, regulatory review and approval, and commercialization of products are forward- looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: failure to achieve anticipated savings from cost- cutting efforts; market acceptance of products; variability of installation and sales cycle including customer financing and construction delays; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward- looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.



                             Accuray Incorporated
          Unaudited Condensed Consolidated Statements of Operations
                    (in thousands, except per share data)

                              Three months ended         Six months ended
                           December 27, December 29, December 27, December 29,
                              2008         2007         2008         2007
    Net revenue:
      Products              $41,301      $39,131      $78,756      $76,115
      Shared ownership
       program                  876        3,044        1,912        5,356
      Services               13,922        8,950       29,829       15,949
      Other                   1,538          913        2,997        3,264
      Total net revenue      57,637       52,038      113,494      100,684
    Cost of revenue:
      Cost of products       17,520       16,481       32,264       32,921
      Cost of shared
      ownership program         207          760          469        1,472
      Cost of services        8,972        6,391       20,157       10,849
      Cost of other           1,529          544        2,766        1,669
      Total cost of revenue  28,228       24,176       55,656       46,911
      Gross profit           29,409       27,862       57,838       53,773
    Operating expenses:
      Selling and marketing  10,723       11,167       24,203       21,323
      Research and
       development            8,794        8,128       17,548       15,843
      General and
       administrative         9,259        7,976       19,692       15,877
      Total operating
       expenses              28,776       27,271       61,443       53,043
    Income (loss) from
     operations                 633          591       (3,605)         730
    Interest and other
     income, net                748        2,197        1,861        4,809
    Income (loss) before
     provision for income
     taxes and cumulative
     effect of change in
     accounting principle     1,381        2,788       (1,744)       5,539
    Provision for income
     taxes                       31          445           85          931
    Net income (loss)        $1,350       $2,343      $(1,829)      $4,608

    Net income (loss)
     per common share,
     basic and diluted:
      Basic                   $0.02        $0.04       $(0.03)       $0.08
      Diluted                 $0.02        $0.04       $(0.03)       $0.08

    Weighted average
     common shares
     outstanding used
     in computing net
     income (loss)
     per share:
      Basic                  55,064       54,737       54,845       54,380
      Diluted                58,267       61,293       54,845       61,257

    Cost of revenue,
     selling and marketing,
     research and
     development, and
     general and
     administrative expenses
     include stock-based
     compensation charges
     as follows:
      Cost of revenue          $547         $530       $1,179         $851
      Selling and
       marketing               $935       $1,039       $1,980       $2,146
      Research and
       development             $751         $803       $1,533       $1,478
      General and
       administrative        $1,348       $1,911       $3,860       $4,112



                             Accuray Incorporated
               Unaudited Condensed Consolidated Balance Sheets
                     (in thousands, except share amounts)

                                                  December 27,     June 28,
                                                      2008           2008
    Assets
    Current assets:
      Cash and cash equivalents                      $29,373        $36,936
      Restricted cash                                    581          4,830
      Short-term marketable securities                80,242         85,536
      Accounts receivable, net of allowance
       for doubtful accounts of $195
       at December 31, 2008 and $27
       at June 30, 2008                               40,935         33,918
      Inventories                                     24,080         23,047
      Prepaid expenses and other current
       assets                                          8,824          6,431
      Deferred cost of revenue-current                21,968         31,667
        Total current assets                         206,003        222,365
    Long-term marketable securities                   44,487         37,014
    Property and equipment, net                       16,158         17,140
    Goodwill                                           4,495          4,495
    Intangible assets, net                               797            926
    Deferred cost of revenue-noncurrent               12,209         11,724
    Other assets                                       1,402          1,340
        Total assets                                $285,551       $295,004

    Liabilities and stockholders' equity
    Current liabilities:
      Accounts payable                                $9,329        $12,962
      Accrued expenses                                16,713         11,873
      Customer advances-current                       17,408         22,331
      Deferred revenue-current                        69,453         87,455
        Total current liabilities                    112,903        134,621
    Long-term liabilities:
      Customer advances-noncurrent                     1,500          2,900
      Deferred revenue-noncurrent                     28,538         26,720
        Total liabilities                            142,941        164,241

    Stockholders' equity
      Preferred stock, $0.001 par value;
       authorized: 5,000,000 shares; no
       shares issued and outstanding.

      Common stock, $0.001 par value;
       authorized: 100,000,000 shares;
       issued: 57,697,449 and 56,719,864
       shares at December 31, 2008 and
       June 30, 2008, respectively;
       outstanding: 55,557,431 and
       54,579,846 shares at December 31,
       2008 and June 30, 2008, respectively.              56             55
      Additional paid-in capital                     264,970        252,901
      Accumulated other comprehensive
       income (loss)                                     539         (1,067)
      Accumulated deficit                           (122,955)      (121,126)
        Total stockholders' equity                   142,610        130,763
        Total liabilities and stockholders'
         equity                                     $285,551       $295,004

SOURCE Accuray Incorporated


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts